A recombinant human insulin expressed in E.coli for treatment of Type 1 and 2 diabetes.

The worldwide market for insulin is over US$5.5 billion and is growing at the rate of 20% per annum.  SciGen is currently targeting countries in the Asia Pacific region and will soon expand into the worldwide market once its manufacturing facility in India starts production.